KR101455842B1 - Anti-Inflammation Composition and an Improvment Composition of Atopic Dermatitis Using an Extract of Immature Fruit of Diospyros kaki - Google Patents
Anti-Inflammation Composition and an Improvment Composition of Atopic Dermatitis Using an Extract of Immature Fruit of Diospyros kaki Download PDFInfo
- Publication number
- KR101455842B1 KR101455842B1 KR1020120122087A KR20120122087A KR101455842B1 KR 101455842 B1 KR101455842 B1 KR 101455842B1 KR 1020120122087 A KR1020120122087 A KR 1020120122087A KR 20120122087 A KR20120122087 A KR 20120122087A KR 101455842 B1 KR101455842 B1 KR 101455842B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- extract
- atopic dermatitis
- present
- inflammatory
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- 239000000284 extract Substances 0.000 title claims abstract description 70
- 206010012438 Dermatitis atopic Diseases 0.000 title abstract description 38
- 201000008937 atopic dermatitis Diseases 0.000 title abstract description 38
- 206010061218 Inflammation Diseases 0.000 title description 8
- 244000236655 Diospyros kaki Species 0.000 title description 3
- 235000008597 Diospyros kaki Nutrition 0.000 title description 2
- 235000013399 edible fruits Nutrition 0.000 title 1
- 239000004480 active ingredient Substances 0.000 claims description 12
- 239000002537 cosmetic Substances 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 19
- 210000004027 cell Anatomy 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 15
- 238000004519 manufacturing process Methods 0.000 abstract description 15
- 102100023698 C-C motif chemokine 17 Human genes 0.000 abstract description 13
- 230000002757 inflammatory effect Effects 0.000 abstract description 13
- 102000004127 Cytokines Human genes 0.000 abstract description 9
- 108090000695 Cytokines Proteins 0.000 abstract description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 7
- 230000006872 improvement Effects 0.000 abstract description 4
- 210000002540 macrophage Anatomy 0.000 abstract description 4
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- -1 hexyl glycol Chemical class 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 16
- 239000000463 material Substances 0.000 description 15
- 230000000845 anti-microbial effect Effects 0.000 description 13
- 102100036845 C-C motif chemokine 22 Human genes 0.000 description 12
- 108010082169 Chemokine CCL17 Proteins 0.000 description 12
- 108010083701 Chemokine CCL22 Proteins 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 12
- 239000000344 soap Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 239000006210 lotion Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical class OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 102100040247 Tumor necrosis factor Human genes 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 239000000469 ethanolic extract Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 7
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 208000027866 inflammatory disease Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 239000004909 Moisturizer Substances 0.000 description 4
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 4
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 4
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 230000001333 moisturizer Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 3
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical class CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- QPUYECUOLPXSFR-UHFFFAOYSA-N 1-methylnaphthalene Chemical compound C1=CC=C2C(C)=CC=CC2=C1 QPUYECUOLPXSFR-UHFFFAOYSA-N 0.000 description 2
- 244000144927 Aloe barbadensis Species 0.000 description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101001056976 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) Catalase-peroxidase Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 2
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 235000021096 natural sweeteners Nutrition 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 229940027779 persimmon extract Drugs 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 230000006461 physiological response Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000006150 trypticase soy agar Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical class O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100021936 C-C motif chemokine 27 Human genes 0.000 description 1
- 101710112538 C-C motif chemokine 27 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 239000004386 Erythritol Chemical class 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Chemical class OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 231100000416 LDH assay Toxicity 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Chemical class 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PSUBPFRWJHQJIA-UHFFFAOYSA-K [Ca+2].C(C=CC=CC)(=O)[O-].[Na+].C(C=CC=CC)(=O)[O-].C(C=CC=CC)(=O)[O-] Chemical compound [Ca+2].C(C=CC=CC)(=O)[O-].[Na+].C(C=CC=CC)(=O)[O-].C(C=CC=CC)(=O)[O-] PSUBPFRWJHQJIA-UHFFFAOYSA-K 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 229940095602 acidifiers Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000004301 calcium benzoate Substances 0.000 description 1
- 235000010237 calcium benzoate Nutrition 0.000 description 1
- HZQXCUSDXIKLGS-UHFFFAOYSA-L calcium;dibenzoate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 HZQXCUSDXIKLGS-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- QGPKADBNRMWEQR-UHFFFAOYSA-N clinafloxacin Chemical compound C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QGPKADBNRMWEQR-UHFFFAOYSA-N 0.000 description 1
- 229950001320 clinafloxacin Drugs 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 210000003426 epidermal langerhans cell Anatomy 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical class OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000003350 kerosene Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 229940073020 nitrol Drugs 0.000 description 1
- 208000037916 non-allergic rhinitis Diseases 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical class CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Chemical class 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001296 polysiloxane Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 229940119485 safflower extract Drugs 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/44—Ebenaceae (Ebony family), e.g. persimmon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 감 미숙과 추출물을 이용한 항염증용 조성물 및 아토피성 피부염 개선용 조성물을 개시한다. 구체적으로 LPS로 자극된 대식세포에서 NO, PGE2, 염증성 사이토카인 등의 생성 억제 활성을 가지고, hIFN-γ, TNF-α로 처리된 각질형성세포주인 HaCaT 세포에서 MDC 및 TARC 생성 억제 활성을 가지는 감 미숙과 추출물을 이용한 항염증용 조성물 및 아토피성 피부염 개선용 조성물을 개시한다.The present invention discloses a composition for antiinflammation and an composition for improving atopic dermatitis using an extract and an extract. Specifically, in the LPS-stimulated macrophages, NO, PGE 2 , The present invention relates to a composition for inhibiting the production of MDC and TARC in HaCaT cells, which have the activity of inhibiting the production of inflammatory cytokines, such as hIFN-γ and TNF-α, and a composition for antiinflammation using the extracts and atopic dermatitis A composition for improvement is disclosed.
Description
본 발명은 감(Diospyros kaki) 미숙과 추출물을 이용한 항염증용 조성물 및 아토피성 피부염 개선용 조성물에 관한 것이다.
The invention persimmon (Diospyros kaki ), and compositions for improving atopic dermatitis.
염증은 외부의 물리·화학적 자극, 박테리아, 곰팡이, 바이러스, 각종 알레르기 유발 물질 등 외부 감염원의 감염에 대한 생체의 방어 반응이다. Inflammation is the defensive response of a living body to external infectious agents such as external physical and chemical stimuli, bacteria, fungi, viruses and allergens.
염증 반응은 선천성 면역 반응의 일부이며, 다른 동물에서처럼 인간의 선천성 면역 반응은 대식세포가 병원체에 특이적으로 존재하는 세포 표면의 패턴을 통해 비자기(non-self)로 인식하고 공격함으로써 시작된다. 염증 반응 시에는 염증 부위에 혈장이 축적되어 세균이 분비한 독성을 희석시키며, 혈류가 증가하고, 홍반, 통증, 부종, 발열 등의 증상이 수반되게 된다.The inflammatory response is part of the innate immune response, and as in other animals, the innate immune response of humans begins by recognizing and attacking macrophages as non-self through a pattern of cell surfaces that are specific to the pathogen. During the inflammation reaction, plasma accumulates on the inflamed area, diluting the toxicities secreted by the bacteria, increasing the blood flow, and accompanied by symptoms such as erythema, pain, edema, and fever.
이러한 염증 반응에는 다양한 생화학적 현상이 관여하는데, 특히 산화질소 합성효소(nitric oxide synthase, NOS)와 다양한 프로스타글란딘(prostaglandins)의 생합성과 관련되는 사이클로옥시제나제(cyclooxygenase, COX)가 염증 반응의 중요한 매개체로 알려져 있다. These inflammatory reactions involve a variety of biochemical events, in particular, cyclooxygenase (COX), which is associated with the nitric oxide synthase (NOS) and the biosynthesis of various prostaglandins, .
NOS는 세 가지 이성질체가 존재하는데, 칼슘이나 카모듈린 의존성인 eNOS(내피성 NOS)와 nNOS(신경성 NOS), 그리고 LPS(lipopolysaccharide)와 같은 세균의 내독소나 IL-1β, TNF-α, IL-6, IL-8, IL-12과 같은 여러 염증성 사이토카인에 의해 유도되는 iNOS(유도성 NOS)가 있으며, L-아르기닌(L-arginine)으로부터 산화질소(NO)를 생성한다. There are three isomers of NOS: endotoxin of bacteria such as calcium or camodanol-dependent eNOS (endothelial NOS), nNOS (neurotic NOS), and lipopolysaccharide (IL-1β, TNF-α, IL There are iNOS (inducible NOS) induced by various inflammatory cytokines such as IL-6, IL-8 and IL-12 and produce NO from L-arginine.
eNOS나 nNOS에 의해 생성되는 NO는 혈압 조절 작용, 신경 전달 작용, 학습, 기억 등과 관련된 다양한 생리 반응을 수행함으로써 인체의 항상성 유지에 중요한 역할을 하지만, iNOS에 의해 생성되는 NO는 관절염, 패혈증, 조직이식거부반응, 자가면역질환, 신경세포의 사멸 등 다양한 염증성 질환에 관여하는 것으로 알려져 있다(Moncade S. et al, Pharmacol. Rev., 1991, 43, 109; Nature Medicine, 2001, 7, 1138; Mu, M. M., J. Endotoxic Res. 7, p341, 2001).NO produced by eNOS or nNOS plays an important role in maintenance of homeostasis by performing various physiological responses related to blood pressure control, neurotransmission, learning, memory, etc. However, NO produced by iNOS is associated with arthritis, sepsis, (Moncade S. et al, Pharmacol. Rev., 1991, 43, 109, Nature Medicine, 2001, 7, 1138; Mu, S., et al., Immunoprecipitation, , MM, J. Endotoxic Res. 7, p341, 2001).
COX 효소는 COX의 기능과 함께 하이드로퍼옥시다제(hydroperoxidase, HOX) 활성을 가지고 아라키돈산으로부터 중간체인 PGG2와 PGH2를 합성하며, 이들 화합물로 PGE2, PGF2, PGD2, 프로스타시클린 및 트롬복신A2(thromboxane A2, TxA2)를 만든다. COX의 기능 중 PGH 합성효소의 기능은 PGE2의 합성을 통해 통증과 염증 반응에 관여한다. The COX enzyme synthesizes PGG 2 and PGH 2 from arachidonic acid with hydroperoxidase (HOX) activity together with the function of COX. These compounds include PGE 2 , PGF 2 , PGD 2 , prostacyclin and create a duplex thromboxane a 2 (thromboxane A2, TxA2) . Among the functions of COX, the function of PGH synthase is involved in the pain and inflammation reaction through synthesis of PGE 2 .
COX에는 두 가지 아형이 있고 COX-1은 대부분의 조직에 항시 발현되는데 비해, COX-2는 염증성 사이토카인에 의해 신속히 발현이 유도되어 염증 반응에서 중요한 역할을 한다. There are two subtypes of COX and COX-1 is always expressed in most tissues, whereas COX-2 is rapidly induced by inflammatory cytokines and plays an important role in the inflammatory response.
따라서 NO, PGE2, 염증성 사이토카인 등의 생성 억제제는 염증질환 치료제로서 활용될 수 있다.Therefore, NO, PGE 2 , Inflammatory cytokine production inhibitors can be used as therapeutic agents for inflammatory diseases.
한편 아토피는 라틴어 'atopia'에서 유래한 말로서 '괴상한' 또는 "부적절한"의 의미를 가지고 있다.On the other hand, atopy is derived from the Latin word 'atopia' and has the meaning of 'odd' or 'inappropriate'.
아토피성 피부염의 원인은 아직까지 명확히 규명되어 있지 않지만, IgE 생성의 증가, CD8+ 억제/세포독성 T 림프구 (CD8+ suppressor/cytotoxic T lymphocytes) 수적 감소와 기능 저하, IFN-γ를 분비하는 Th1(T-cell Helper type 1) 림프구의 수적 감소, 단핵구/대식세포의 침윤, 비만세포, 호산구, 수지상세포(dendritic cells; DCs), 표피의 랑게르한스 세포 및 CD4+ T 림프구의 수적 증가, Th1 세포에 비해 Th2 세포의 수적 증가, 사이토카인(IL-10, IL-4, IL-5, TNF-α 등)의 생성 증가, 케모카인(TSLP, RANTES, CTACK, LARC, MDC, TARC 등)의 생성 증가 등의 면역학적 현상들이 보고되고 있고[J. Invest. Dermatol., 96:523-526, 1991; J. Invest Dermatol., 97:389-394, 1991; Immunol., 11:81-88, 1999; Curr Drug Targets Inflamm Allergy., 2:199-120, 2003; J. Allergy Clin Immunol., 107:871-877, 2001; Adv. Immunol. 78:57, 2001; International Immunology, 14(7):767-773, 2002; Pediatr Allergy Immunol 19: 605-613, 2008], 통상 아토피성 피부염을 앓고 있는 사람이 집 먼지, 진드기, 동물의 털, 음식물, 꽃가루, 곰팡이 등과 같이 외부환경의 이물질에 대해 알러지 반응을 나타내는 점과 또 아토피성 피부염이 알러지성 비염, 천식, 결막염, 장관염 등을 동반한다는 점에서 면역 체계의 교란에 의하여 발생하는 것으로 추정되고 있다.The cause of atopic dermatitis has not yet been clarified yet. However, the cause of atopic dermatitis is not clear, but the number of IgE production, CD8 + suppression / cytotoxic T lymphocyte decrease and dysfunction, Th1 (T- cell Helper type 1) Numerical increase of lymphocyte, mononuclear / macrophage infiltration, mast cell, eosinophil, dendritic cells (DCs), increase of epidermal Langerhans cell and CD4 + T lymphocyte, Increased production of cytokines (IL-10, IL-4, IL-5, TNF-α, etc.) and increased production of chemokines (TSLP, RANTES, CTACK, LARC, MDC, TARC etc.) Have been reported [J. Invest. Dermatol., 96: 523-526,1991; J. Invest. Dermatol., 97: 389-394,1991; Immunol., 11: 81-88, 1999; Curr Drug Targets Inflamm Allergy., 2: 199-120, 2003; J. Allergy Clin Immunol., 107: 871-877, 2001; Adv. Immunol. 78:57, 2001; International Immunology, 14 (7): 767-773, 2002; Pediatr Allergy Immunol 19: 605-613, 2008], a person suffering from atopic dermatitis generally exhibits an allergic reaction to foreign substances such as house dust, ticks, animal hair, food, pollen and mold, It is presumed that atopic dermatitis is caused by disturbance of the immune system in that it accompanies allergic rhinitis, asthma, conjunctivitis and intestinal inflammation.
아토피성 피부염 활성 물질의 스크리닝을 위하여 비만세포를 이용한 탈과립 억제 활성 실험, 각질형성세포에서의 MDC(macrophage-derived chemokine)와 TARC(thymusand activation-regulated chemokine)의 발현 수준의 측정 실험 등이 이용되고 있는데, 상기 MDC와 TARC는 아토피성 피부염 환자에서 그 혈청 농도가 현저히 증가한다고 보고된 케모카인으로서(Hijnen et. al., J. Allergy Clin. Immunol. 113(2) 334-340), 아토피성 피부염의 치료 물질로 사용되는 사이크로스포린 A나 코르티코스테로이드를 아토피성 피부염 환자에게 투여하였을 때는 MDC 및 TARC의 혈청 농도가 감소한다는 보고가 있으며(Y. Shimada et al., J. Dermatol. Sci., 34, 201-208, 2004), 또 사람 각질형성세포주인 HaCaT 세포에 hIFN-γ, TNF-α를 처리하였을 때 MDC 및 TARC가 다량 발현되는데 이러한 발현을 억제할 수 있는 물질은 아토피성 피부염 치료제로 사용될 수 있음이 제시된 바 있다(Horikawa et. al., Int. Immunol., 14(7) 767-773, 2002).Experiments for inhibiting degranulation using mast cells for the screening of atopic dermatitis active substances and experiments for measuring the expression levels of MDC (macrophage-derived chemokine) and TARC (thymus and activation-regulated chemokine) in keratinocytes , MDC and TARC are chemokines reported to have significantly increased serum levels in patients with atopic dermatitis (Hijnen et al., J. Allergy Clin. Immunol. 113 (2) 334-340), treatment of atopic dermatitis It has been reported that when ciclosporin A or corticosteroids are administered to patients with atopic dermatitis, the serum levels of MDC and TARC are decreased (Y. Shimada et al., J. Dermatol. Sci., 34, 201 -208, 2004), and when hIFN-γ and TNF-α were treated with human keratinocyte cell line HaCaT cells, MDC and TARC were expressed in large quantities. Substances capable of inhibiting such expression are atopic dermatitis (Horikawa et al., Int. Immunol., 14 (7) 767-773, 2002).
본 발명은 LPS로 자극된 대식세포에서 NO, PGE2, 염증성 사이토카인 등의 생성 억제 활성을 가지고, hIFN-γ, TNF-α가 처리된 HaCaT 세포에서 MDC 및 TARC 생성 억제 활성을 가지는 감 미숙과 추출물을 개시한다.
The present invention is based on the finding that NO, PGE 2 , And extracts of Haemaphylococcus epidermidis having inhibitory activity against the production of MDC and TARC in hIFN-y and TNF-a treated HaCaT cells.
본 발명의 목적은 감 미숙과 추출물을 이용한 항염증용 조성물과 아토피성 피부염 개선용 조성물을 제공하는 데 있다.It is an object of the present invention to provide a composition for antiinflammation using an extract and a composition for improving atopic dermatitis.
본 발명의 기타의 목적이나 구체적인 목적은 이하에서 제시될 것이다.
Other objects and specific objects of the present invention will be described below.
본 발명자들은 아래의 실시예 및 실험예에서 확인되는 바와 같이, 감 미숙과의 압착 추출액과 그것의 1년, 3년 숙성물을 제조하고 그것의 항염증 활성을 LPS로 자극된 대식세포에서 NO, PGE2, 염증성 사이토카인 등의 생성 억제 활성을 통하여 확인한 결과 감 미숙과의 압착 추출액, 그것의 1년, 3년 숙성물 순으로 항염증 활성이 높아짐을 확인하였다. As shown in the following Examples and Experimental Examples, the inventors of the present invention prepared a 1-year, 3-year aged product with a pressurized extract and an anti-inflammatory activity thereof in a macrophage stimulated with LPS, PGE 2 , Inflammatory cytokine. The results showed that the anti - inflammatory activity was increased in the order of 1 - year and 3 - year aged extracts.
본 발명자들은 또한 감 미숙과를 실온, 60℃ 및 100℃ 조건에서 증류수로 추출하는 한편 또 30%와 70% 에탄올로 추출하여 각 추출 조건별 추출물을 제조하고 이들 추출물의 아토피성 피부염 개선 활성을 hIFN-γ, TNF-α로 처리된 HaCaT 세포에 처리하여 MDC 및 TARC 생성 억제 활성을 통하여 확인한 결과 100℃ 추출물과 30% 에탄올 추출물이 특별히 높은 활성을 보임을 확인하였으며, 이러한 세포실험 결과에 기초하여 실온 추출물, 100℃ 추출물 그리고 30% 에탄올 추출물이 각각 함유된 3종의 영양로션을 이용하여 8주간의 임상시험을 실시하였는데, 세포실험에서 활성이 높은 것으로 확인된 100℃ 추출물과 30% 에탄올 추출물이 실온 추출물에 비하여 뚜렷하게 높은 아토피성 피부염 개선 활성을 보임을 확인하였다. The present inventors also extracted extracts of 30% and 70% ethanol with distilled water at room temperature, 60 ° C, and 100 ° C, respectively, to prepare extracts for each extraction condition. The extracts of atopic dermatitis were divided into hIFN -γ, and TNF-α. The results showed that the extracts of 100 ℃ and 30% ethanol showed high activity especially on the MDC and TARC production inhibitory activities. The extracts of 100 ℃ and 30% ethanol extracts which were found to be highly active in cell experiments were incubated at room temperature (100 ℃) and 30% ethanol extract The extracts showed markedly higher activity against atopic dermatitis.
전술한 바의 실험 결과를 고려할 때, 본 발명의 항염증성 조성물은 감 미숙과 추출물, 특히 감 미숙과 압착 추출액(감 미숙과를 물리적 외력으로 압착하여 얻어진 추출액)의 숙성물을 유효성분으로 포함하는 항염증용 조성물로 파악할 수 있으며, 다른 측면에 있어서는 감 미숙과 100℃의 열수 추출물 또는 감 미숙과의 30% 에탄올 추출물을 유효성분으로 포함하는 아토피성 피부염 개선용 조성물로 파악할 수 있다. 여기서 "%"는 부피 백분율에 의한 농도(v/v) 표현으로서, 당업계에 알려진 바와 같이 일정 부피의 용액 중에 녹아 있는 일정 부피의 용질을 의미한다. 예컨대 30%(v/v) 에탄올은 물 100㎖에 에탄올 30㎖가 용해되어 있다는 것이 된다.In view of the above-mentioned experimental results, the anti-inflammatory composition of the present invention is characterized in that the anti-inflammatory composition of the present invention contains an aged product of an undiluted extract and an extract, particularly an undiluted extract and a pressurized extract (an extract obtained by pressing the unrefined undiluted extract with a physical external force) In another aspect, the composition can be identified as a composition for improving atopic dermatitis, which comprises an extract of hot-water extract at 100 ° C or a 30% ethanol extract of unripe starch as an active ingredient. Where "%" is the concentration (v / v) by volume percentage and refers to a volume of solute dissolved in a volume of solution as is known in the art. For example, 30% (v / v) ethanol means that 30 ml of ethanol is dissolved in 100 ml of water.
본 명세서에서, "감 미숙과"란 수확기 이전의 감(과실)을 의미하며, 보다 구체적으로 그 표면이 완전히 녹색인 상태의 감을 의미한다. In the present specification, the term " undamaged seed "means a sense before the harvest, more specifically, a sense that the surface is completely green.
또 본 명세서에서, "유효성분"이란 단독으로 목적하는 활성을 나타내거나 또는 그 자체는 활성이 없는 담체와 함께 활성을 나타낼 수 있는 성분을 의미한다.In the present specification, the term "active ingredient" alone means an ingredient which exhibits the desired activity or can exhibit activity together with a carrier which is not itself active.
또 본 명세서에서, "항염증"은 아래에서 정의되는 염증성 질환의 개선, 치료, 그러한 질환의 발병 억제 또는 지연을 포함하는 의미이다.As used herein, "anti-inflammatory" is meant to include the improvement, treatment, inhibition or delay of the onset of an inflammatory disease as defined below.
또 본 명세서에서, "염증성 질환"이란 외부의 물리·화학적 자극 또는 박테리아, 곰팡이, 바이러스, 각종 알레르기 유발 물질 등 외부 감염원의 감염에 대해 국부적 또는 전신적 생체 방어 반응으로 특정되는 염증 반응을 수반하는 질환으로서 정의될 있다. 이러한 염증 반응을 수반하는 질환은 각종 염증 매개 인자와 면역세포와 관련된 효소(예컨대 iNOS, COX-2 등) 활성화, 염증 매개 물질의 분비(예컨대, NO, TNF-α, IL-6, IL-1β, PGE2의 분비), 체액 침윤, 세포 이동, 조직 파괴 등의 일련의 복합적인 생리적 반응을 수반하며, 홍반, 통증, 부종, 발열, 신체의 특정 기능의 저하 또는 상실 등의 증상에 의해 외적으로 나타난다. 상기 염증성 질환은 급성, 만성, 궤양성, 알레르기성 또는 괴사성을 띨 수 있으므로, 어떠한 질환이 상기와 같은 염증성 질환의 정의에 포함되는 한 그것이 급성이든지, 만성이든지, 궤양성이든지, 알레르기성이든지 또는 괴사성이든지를 불문한다. 구체적으로 상기 염증성 질환에는 천식, 알레르기성 및 비-알레르기성 비염, 만성 및 급성 비염, 만성 및 급성 위염 또는 장염, 궤양성 위염, 급성 및 만성 신장염, 급성 및 만성 간염, 만성 폐쇄성 폐질환, 폐섬유증, 과민성 대장 증후군, 염증성 통증, 편두퐁, 두통, 허리 통증, 섬유 근육통, 근막 질환, 바이러스 감염(예컨대, C형 감염), 박테리아 감염, 곰팡이 감염, 화상, 외과적 또는 치과적 수술에 의한 상처, 프로스타글라딘 E 과다 증후군, 아테롬성 동맥 경화증, 통풍, 관절염, 류머티스성 관절염, 강직성 척추염, 호지킨병, 췌장염, 결막염, 홍채염, 공막염, 포도막염, 피부염, 습진, 다발성 경화증 등이 포함될 것이다. In the present specification, the term "inflammatory disease" means a disease accompanied by an inflammatory reaction specified by a local or systemic bio-defense reaction against an external infectious source such as external physical or chemical stimuli or bacterial, fungal, Be defined. The diseases accompanied by such an inflammatory reaction include various inflammatory mediators and activations of enzymes (e.g., iNOS, COX-2 etc.) associated with immune cells, secretion of inflammatory mediators such as NO, TNF-a, IL-6, , PGE 2 secretion), body fluid infiltration, cell migration, and tissue destruction, and is accompanied by a series of complex physiological responses such as erythema, pain, edema, fever, deterioration or loss of specific function of the body, appear. The inflammatory disease may be acute, chronic, ulcerative, allergic or necrotic, so long as it is included in the definition of inflammatory diseases as above, it may be acute, chronic, ulcerative, allergic, Whether it is necrotic or not. Specifically, the inflammatory diseases include asthma, allergic and non-allergic rhinitis, chronic and acute rhinitis, chronic and acute gastritis or enteritis, ulcerative gastritis, acute and chronic nephritis, acute and chronic hepatitis, chronic obstructive pulmonary disease, Inflammatory bowel syndrome, inflammatory pain, migraine headache, headache, back pain, fibromyalgia, fascia disease, viral infection (e.g., C type infection), bacterial infection, fungal infection, burn, wound due to surgical or dental surgery, These may include Prostaglandin E Overdose Syndrome, atherosclerosis, gout, arthritis, rheumatoid arthritis, ankylosing spondylitis, Hodgkin's disease, pancreatitis, conjunctivitis, iritis, scleritis, uveitis, dermatitis, eczema and multiple sclerosis.
또 본 명세서에서, "아토피성 피부염"은 그 발생의 직·간접적인 원인을 불문하고 당업계에서 아토피성 피부염으로 분류되는 모든 질환을 포함하는 것으로 정의된다. 통상 아토피성 피부염은 그 발병 시기 또는 그 발명 대상에 따라 유아형 아토피성 피부염, 소아형 아토피성 피부염, 성인형 아토피성 피부염 그리고 임산부 아토피성 피부염으로 분류되는데, 본 명세서에서 아토피성 피부염은 이러한 모든 유형의 아토피성 피부염을 포함한다.As used herein, "atopic dermatitis" is defined as including any disease classified as atopic dermatitis in the art, regardless of the cause, either directly or indirectly, of its occurrence. In general, atopic dermatitis is classified into infantile atopic dermatitis, pediatric atopic dermatitis, adult atopic dermatitis, and maternal atopic dermatitis according to the onset period or the object of the invention. In the present specification, Of atopic dermatitis.
본 발명의 항염증용 조성물 및 아토피성 피부염 개선용 조성물(이하 "본 발명의 조성물")은 그 유효성분인 감 미숙과 추출물 등을 항염증 활성, 아토피성 피부염 개선 활성을 나타낼 수 있는 한 용도, 제형, 배합 목적 등에 따라 임의의 양(유효량)으로 포함할 수 있는데, 통상적인 유효량은 조성물 전체 중량을 기준으로 할 때 0.001 중량 % 내지 99.900 중량 % 범위 내에서 결정될 것이다. 여기서 "유효량"이란 염증성 질환이나 아토피성 피부염의 예방, 개선, 치료, 또는 그 증상의 발현 지연을 유도할 수 있는 유효성분의 양을 말한다. 이러한 유효량은 당업자의 통상의 능력 범위 내에서 실험적으로 결정될 수 있다.The composition for antiinflammation and the composition for improving atopic dermatitis of the present invention (hereinafter, referred to as "composition of the present invention") can be used for an anti-inflammatory activity, an atopic dermatitis- (Effective amount) depending on the purpose of administration, formulation, purpose of formulation, etc. A typical effective amount will be determined within the range of 0.001 wt% to 99.900 wt% based on the total weight of the composition. The term "effective amount" as used herein refers to an amount of an effective ingredient capable of inducing prevention, amelioration, treatment, or delayed onset of symptoms of an inflammatory disease or atopic dermatitis. Such effective amounts can be determined experimentally within the ordinary skill of those skilled in the art.
본 발명의 조성물은 구체적인 양태에 있어서 화장품 조성물로 파악할 수 있다.The composition of the present invention can be identified as a cosmetic composition in a specific embodiment.
본 발명의 조성물이 화장품 조성물로서 파악될 경우, 그 화장품 조성물은 다양한 형태로 제조될 수 있는데, 예컨대, 에멀젼, 로션, 크림(수중유적형, 유중수적형, 다중상), 용액, 현탁액(무수 및 수계), 무수 생성물(오일 및 글리콜계), 젤, 마스크, 팩 또는 분말 등의 제형으로 제조될 수 있다.When the composition of the present invention is recognized as a cosmetic composition, the cosmetic composition may be prepared in various forms, for example, emulsion, lotion, cream (oil-in-water type, oil water type, multiphase), solution, suspension Water, water), anhydrous products (oil and glycol), gels, masks, packs or powders.
본 발명의 조성물은 그 유효성분 이외에 화장품 제제에 있어서 수용가능한 담체를 포함할 수 있다. The composition of the present invention may contain an acceptable carrier in cosmetic preparations in addition to its active ingredients.
여기서 "화장품 제제에 있어서 수용가능한 담체"란 화장품 제제에 포함될 수 있는 이미 공지되어 사용되고 있는 화합물 또는 조성물이거나 앞으로 개발될 화합물 또는 조성물로서 피부와의 접촉시 인체가 적응 가능한 독성 이상의 독성이 없는 것을 말한다.As used herein, the term " acceptable carrier for a cosmetic preparation "refers to a compound or composition which is already known and used in the cosmetic preparation, or which is a compound or composition to be developed in the future, and which is not toxic to the human body.
상기 담체는 본 발명의 조성물에 그것의 전체 중량에 대하여 약 1 중량 % 내지 약 99.99 중량 %, 바람직하게는 조성물의 중량의 약 50 중량% 내지 약 99 중량 %로 포함될 수 있다. The carrier may be included in the composition of the present invention in an amount of from about 1% by weight to about 99.99% by weight, preferably from about 50% by weight to about 99% by weight of the composition, based on the total weight thereof.
그러나 상기 비율은 화장품의 전술한 바의 제형에 따라 또 그것의 구체적인 적용 부위(얼굴이나 손)나 그것의 바람직한 적용량 등에 따라 달라지는 것이기 때문에, 상기 비율은 어떠한 측면으로든 본 발명의 범위를 제한하는 것으로 이해되어서는 안 된다. However, since the ratio depends on the above-mentioned formulation of the cosmetic product and its specific application site (face or hands) or the desired amount of application thereof, the ratio is to limit the scope of the present invention in any aspect It should not be.
한편, 상기 담체로서는 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선 차단제, 발색제, 향료 등이 예시될 수 있다. Examples of the carrier include alcohols, oils, surfactants, fatty acids, silicone oils, humectants, moisturizers, viscosifiers, emulsifiers, stabilizers, sunscreens, coloring agents and perfumes.
상기 담체로서 사용될 수 있는 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 습윤제, 보습제, 점성 변형제, 유제, 안정제, 자외선 차단제, 발색제, 향료 로 사용될 수 있는 화합물/조성물 등은 이미 당업계에 공지되어 있기 때문에 당업자라면 적절한 해당 물질/조성물을 선택하여 사용할 수 있다.The compounds / compositions which can be used as the carrier and which can be used as alcohols, oils, surfactants, fatty acids, silicone oils, wetting agents, moisturizers, viscosifiers, emulsions, stabilizers, sunscreens, A person skilled in the art can select and use appropriate substances / compositions.
본 발명의 조성물은 또 다른 구체적인 양태에 있어 비누 조성물로서 파악될 수 있다.The composition of the present invention can be identified as a soap composition in another specific embodiment.
본 발명의 조성물이 비누 조성물로서 파악될 경우에, 본 발명의 비누 조성물은 비누 기재에 유효성분을 포함하여 제조될 수 있으며, 첨가제로서 피부 보습제, 유화제, 경수 연화제 등을 포함하여 제조될 수 있다.When the composition of the present invention is identified as a soap composition, the soap composition of the present invention can be prepared by incorporating an active ingredient into a soap base, and can be prepared as an additive including a skin moisturizer, an emulsifier, a water softener and the like.
상기 비누 기재로서는 야자유, 팜유, 대두유, 파마자유, 올리브유, 팜핵류 등의 식물유지 또는 우지, 돈지, 양지, 어유 등의 동물유지 등이 사용될 수 있고, 상기 피부 보습제로서는 글리세린, 에리트리톨, 폴리에틸렌글리콜, 프로필렌글리콜, 부틸렌글리콜, 펜틸렌글리콜, 헥실글리콜, 이소프로필미리스테이트, 실리콘 유도체, 알로에베라, 솔비톨 등이 사용될 수 있으며, 상기 유화제로서는 천연오일, 왁스 지방알콜, 탄화수소류, 천연식물 추출물 등이 사용될 수 있고, 상기 경수연화제로서는 테트라소듐 이디티에이 등이 사용될 수 있다.Examples of the soap base material include vegetable oils such as palm oil, palm oil, soybean oil, perm free oil, olive oil and palm kernel oil or animal fats such as tallow, lard, sunshine and fish oil. Examples of the skin moisturizers include glycerin, erythritol, polyethylene glycol , Propylene glycol, butylene glycol, pentylene glycol, hexyl glycol, isopropyl myristate, silicone derivatives, aloe vera, sorbitol and the like. Examples of the emulsifier include natural oils, wax fatty alcohols, hydrocarbons, May be used. As the water softening agent, tetrasodium ethylenediate and the like may be used.
본 발명의 비누 조성물은 또한 첨가제로서 항균제, 분산제, 거품억제제, 용매, 물때 방지제, 부식 방지제, 향료, 색소, 금속이온 봉쇄제, 산화방지제, 방부제 등을 추가적으로 포함할 수 있다.The soap composition of the present invention may further contain, as an additive, an antibacterial agent, a dispersant, a foam inhibitor, a solvent, a scouring inhibitor, a corrosion inhibitor, a fragrance, a dye, a sequestering agent, an antioxidant and an antiseptic.
본 발명의 비누 조성물에 있어서, 비누 기재나 첨가제는 당업계에 일반적으로 사용되고 있는 함량으로 포함될 수 있는데, 비누 기재는 일반적으로 비누 조성물의 전체 중량을 기준으로 하였을 때 99.999 중량 % 내지 50 중량 %로 첨가될 수 있으며, 첨가제는 1 중량 % 내지 20 중량 %로 첨가될 수 있다. In the soap composition of the present invention, the soap base or additive may be included in a content commonly used in the art, wherein the soap base generally comprises from 99.999% to 50% by weight, based on the total weight of the soap composition And the additive may be added in an amount of 1 wt% to 20 wt%.
본 발명의 조성물은 다른 구체적인 양태에 있어서 약제학적 조성물로 파악될 수 있다.The composition of the present invention can be identified as a pharmaceutical composition in another specific embodiment.
본 발명의 약제학적 조성물은 그 유효성분 이외에 약제학적으로 허용되는 담체, 부형제 등을 포함하여, 경구용 제형(정제, 현탁액, 과립, 에멀젼, 캡슐, 시럽 등), 비경구형 제형(멸균 주사용 수성 또는 유성 현탁액), 국소형 제형(크림, 로션, 연고(반고형의 외용약), 마이크로로에멀젼, 젤, 페이스트, 경피제제(TTS)(예컨대 패치제, 붕대 등) 등으로 제조될 수 있다.The pharmaceutical composition of the present invention may be in the form of oral formulations (tablets, suspensions, granules, emulsions, capsules, syrups, etc.), parenteral formulations (including sterile injectable aqueous Or oily suspensions), stationary formulations (such as creams, lotions, ointments (semi-solid external preparations), micro loo emulsions, gels, pastes, transdermal preparations (e.g., patches, bandages, etc.).
상기에서 "약제학적으로 허용되는" 의미는 유효성분의 활성을 억제하지 않으면서 적용(처방) 대상이 적응가능한 이상의 독성을 지니지 않는다는 의미이다.The term "pharmaceutically acceptable" as used herein means that the application (prescribing) subject does not have the above-mentioned toxicity that is adaptable without inhibiting the activity of the active ingredient.
약제학적으로 허용되는 담체의 예로서는 락토스, 글루코스, 슈크로스, 전분(예컨대 옥수수 전분, 감자 전분 등), 셀룰로오스, 그것의 유도체(예컨대 나트륨 카르복시메틸 셀룰로오스, 에틸셀룰로오스, 등), 맥아, 젤라틴, 탈크, 고체 윤활제(예컨대 스테아르산, 스테아르산 마그네슘 등), 황산 칼슘, 식물성 기름(예컨대 땅콩 기름, 면실유, 참기름, 올리브유 등), 폴리올(예컨대 프로필렌 글리콜, 글리세린 등), 알긴산, 유화제(예컨대 TWEENS), 습윤제(예컨대 라우릴 황산 나트륨), 착색제, 풍미제, 정제화제, 안정화제, 항산화제, 보존제, 물, 식염수, 인산염 완충 용액 등을 들 수 있다. 이러한 담체는 본 발명의 약제학적 조성물의 제형에 따라 적당한 것을 하나 이상 선택하여 사용할 수 있다.Examples of pharmaceutically acceptable carriers include lactose, glucose, sucrose, starch (e.g., corn starch, potato starch and the like), cellulose, derivatives thereof (e.g. sodium carboxymethylcellulose, ethylcellulose, etc.), malt, gelatin, talc, (E.g., peanut oil, cottonseed oil, sesame oil, olive oil, etc.), polyols (e.g., propylene glycol, glycerin, etc.), alginic acid, emulsifiers (e.g., TWEENS), wetting agents (For example, sodium lauryl sulfate), a coloring agent, a flavoring agent, a tableting agent, a stabilizer, an antioxidant, a preservative, water, a saline solution and a phosphate buffer solution. The carrier may be selected from one or more of suitable pharmaceutical formulations according to the formulation of the pharmaceutical composition of the present invention.
부형제도 본 발명의 약제학적 조성물의 제형에 따라 적합한 것을 선택하여 사용할 수 있는데, 예컨대 본 발명의 약제학적 조성물이 수성 현탁제로 제조될 경우에 적합한 부형제로서는 나트륨 카르복시메틸 셀룰로오스, 메틸 셀룰로오스, 히드로프로필메틸셀룰로오스, 알긴산 나트륨, 폴리비닐피롤리돈 등의 현탁제나 분산제 등을 들 수 있다. 주사액으로 제조되는 경우 적합한 부형제로서는 링거액, 등장 염화나트륨 등을 들 수 있다.The excipient may be selected according to the formulation of the pharmaceutical composition of the present invention. For example, when the pharmaceutical composition of the present invention is prepared by an aqueous suspension, suitable excipients include sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose , Sodium alginate, polyvinylpyrrolidone, and the like. Suitable excipients when prepared from injection solutions include Ringer's solution, isotonic sodium chloride, and the like.
본 발명의 약제학적 조성물은 경구 또는 비경구로 투여될 수 있고, 바람직하게는 국소적으로 투여될 수 있다.The pharmaceutical compositions of the present invention may be administered orally or parenterally, and preferably topically.
본 발명의 약제학적 조성물은 그 1일 투여량이 통상 0.001 ~ 150 mg/kg 체중 범위이고, 1회 또는 수회로 나누어 투여할 수 있다. 그러나, 본 발명의 약제학적 조성물의 투여량은 투여 경로, 환자의 연령, 성별, 체중, 환자의 중증도 등의 여러 관련 인자에 비추어 결정되는 것이므로 상기 투여량은 어떠한 측면으로든 본 발명의 범위를 제한하는 것으로 이해되어서는 아니된다. The daily dose of the pharmaceutical composition of the present invention is usually 0.001 to 150 mg / kg body weight, and may be administered once or several times. However, since the dosage of the pharmaceutical composition of the present invention is determined in view of various related factors such as route of administration, age, sex, weight, and patient's severity of the patient, the dose is limited in any aspect to the scope of the present invention Should not be understood to be.
본 발명의 조성물은 구체적인 양태에 있어서, 기능성 음료 등의 식품 조성물로 파악할 수 있다. In a specific embodiment, the composition of the present invention can be identified by a food composition such as a functional beverage.
본 발명의 식품 조성물에는 그 유효성분 이외에 감미제, 풍미제, 생리활성 성분, 미네랄 등이 포함될 수 있다.The food composition of the present invention may contain sweetening agents, flavoring agents, physiologically active ingredients, minerals and the like in addition to the active ingredients thereof.
감미제는 식품이 적당한 단맛을 나게 하는 양으로 사용될 수 있으며, 천연의 것이거나 합성된 것일 수 있다. 바람직하게는 천연 감미제를 사용하는 경우인데, 천연 감미제로서는 옥수수 시럽 고형물, 꿀, 수크로오스, 프룩토오스, 락토오스, 말토오스 등의 당 감미제를 들 수 있다. Sweetening agents may be used in an amount that sweetens the food in a suitable manner, and may be natural or synthetic. Preferably, natural sweeteners are used. Examples of natural sweeteners include sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose and maltose.
풍미제는 맛이나 향을 좋게 하기 위하여 사용될 수 있는데, 천연의 것과 합성된 것 모두 사용될 수 있다. 바람직하게는 천연의 것을 사용하는 경우이다. 천연의 것을 사용할 경우에 풍미 이외에 영양 강화의 목적도 병행할 수 있다. 천연 풍미제로서는 사과, 레몬, 감귤, 포도, 딸기, 복숭아 등에서 얻어진 것이거나 녹차잎, 둥굴레, 대잎, 계피, 국화 잎, 자스민 등에서 얻어진 것일 수 있다. 또 인삼(홍삼), 죽순, 알로에 베라, 은행 등에서 얻어진 것을 사용할 수 있다. 천연 풍미제는 액상의 농축액이나 고형상의 추출물일 수 있다. 경우에 따라서 합성 풍미제가 사용될 수 있는데, 합성 풍미제는 에스테르, 알콜, 알데하이드, 테르펜 등이 이용될 수 있다. Flavors may be used to enhance taste or flavor, both natural and synthetic. Preferably, a natural one is used. When using natural ones, the purpose of nutritional fortification can be performed in addition to the flavor. Examples of natural flavoring agents include those obtained from apples, lemons, citrus fruits, grapes, strawberries, peaches, and the like, or those obtained from green tea leaves, Asiatica, Daegu, Cinnamon, Chrysanthemum leaves and Jasmine. Also, those obtained from ginseng (red ginseng), bamboo shoots, aloe vera, banks and the like can be used. The natural flavoring agent may be a liquid concentrate or a solid form of extract. Synthetic flavors may be used depending on the case, and synthetic flavors such as esters, alcohols, aldehydes, terpenes and the like may be used.
생리 활성 물질로서는 카테킨, 에피카테킨, 갈로가테킨, 에피갈로카테킨 등의 카테킨류나, 레티놀, 아스코르브산, 토코페롤, 칼시페롤, 티아민, 리보플라빈 등의 비타민류 등이 사용될 수 있다.Examples of the physiologically active substance include catechins such as catechin, epicatechin, gallocatechin and epigallocatechin, and vitamins such as retinol, ascorbic acid, tocopherol, calciferol, thiamine and riboflavin.
미네랄로서는 칼슘, 마그네슘, 크롬, 코발트, 구리, 불소화물, 게르마늄, 요오드, 철, 리튬, 마그네슘, 망간, 몰리브덴, 인, 칼륨, 셀레늄, 규소, 나트륨, 황, 바나듐, 아연 등이 사용될 수 있다.As the mineral, calcium, magnesium, chromium, cobalt, copper, fluoride, germanium, iodine, iron, lithium, magnesium, manganese, molybdenum, phosphorus, potassium, selenium, silicon, sodium, sulfur, vanadium and zinc can be used.
또한 본 발명의 식품 조성물은 상기 감미제 등 이외에도 필요에 따라 보존제, 유화제, 산미료, 점증제 등을 포함할 수 있다. In addition, the food composition of the present invention may contain preservatives, emulsifiers, acidifiers, thickeners and the like as needed in addition to the above sweeteners.
이러한 보존제, 유화제 등은 그것이 첨가되는 용도를 달성할 수 있는 한 극미량으로 첨가되어 사용되는 것이 바람직하다. 극미량이란 수치적으로 표현할 때 식품 조성물 전체 중량을 기준으로 할 때 0.0005중량% 내지 약 0.5중량% 범위를 의미한다.Such preservatives, emulsifiers and the like are preferably added in a very small amount as long as they can attain an application to which they are added. The term " trace amount " means, when expressed numerically, in the range of 0.0005% by weight to about 0.5% by weight based on the total weight of the food composition.
사용될 수 있는 보존제로서는 소듐 소르브산칼슘, 소르브산나트륨, 소르브산칼륨, 벤조산칼슘, 벤조산나트륨, 벤조산칼륨, EDTA(에틸렌디아민테트라아세트산) 등을 들 수 있다. Examples of the preservative which can be used include calcium sodium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate and EDTA (ethylenediaminetetraacetic acid).
사용될 수 있는 유화제로서는 아카시아검, 카르복시메틸셀룰로스, 잔탄검, 펙틴 등을 들 수 있다.Examples of the emulsifier which can be used include acacia gum, carboxymethyl cellulose, xanthan gum, pectin and the like.
사용될 수 있는 산미료로서는 연산, 말산, 푸마르산, 아디프산, 인산, 글루콘산, 타르타르산, 아스코르브산, 아세트산, 인산 등을 들 수 있다. 이러한 산미료는 맛을 증진시키는 목적 이외에 미생물의 증식을 억제할 목적으로 식품 조성물이 적정 산도로 되도록 첨가될 수 있다.Examples of the acidulant that can be used include acid, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, and phosphoric acid. Such an acidulant may be added so that the food composition has a proper acidity for the purpose of inhibiting the growth of microorganisms other than the purpose of enhancing the taste.
사용될 수 있는 점증제로서는 현탁화 구현제, 침강제, 겔형성제, 팽화제 등을 들 수 있다. Agents that may be used include suspending agents, sedimentation agents, gel formers, bulking agents and the like.
한편 본 발명은 또 다른 측면에 있어서, 특히 감 미숙과 압착 추출액의 숙성물을 유효성분으로 포함하는 스타필로코쿠스 아우레우스(Staphylococcus aureus)에 대한 항미생물용 조성물에 관한 것이다.According to another aspect of the present invention, there is provided an antimicrobial composition for Staphylococcus aureus comprising an aged product of unripe and crushed extract as an active ingredient.
아래의 실험예에서 사용된 스타필로코쿠스 아우레우스는 피부 상재균으로서 평상시에는 의학적으로 특별히 문제되지 않으나 면역력이 떨어진 환자들에 대해서는 패혈증, 종기, 여드름 등을 일으키는 것으로 알려져 있는 미생물이다. 본 발명자들은 감 미숙과 압착 추출액과 그 숙성물의 스타필로코쿠스 아우레우스에 대한 항미생물 활성을 최소세균사멸농도를 통하여 확인하였는데, 감 미숙과 압착 추출액의 경우는 최소세균사멸농도가 측정되지 않았으나 그 숙성물의 경우는 2mg/mL의 최소세균사멸농도를 나타내었다.Staphylococcus aureus used in the following experiment is a microorganism which is known to cause septicemia, boils, acne and the like in patients whose skin is not normally a medical problem but immunity is low. The present inventors have confirmed the antimicrobial activity against Staphylococcus aureus in the unsweetened and squeezed extract and its aged material through the minimum bacteriostatic concentration, but the minimum bacteriostatic concentration was not measured in the case of unstained and compressed extracts In the case of the aged material, the minimum bacteriostatic concentration was 2 mg / mL.
본 발명의 항미생물용 조성물은 그 유효성분인 감 미숙과 추출물을 그것이 항미생물 활성을 나타내는 한 임의의 양으로 본 발명의 항미생물용 조성물에 포함될 수 있는데, 통상은 그 조성물 전체 중량을 기준으로 하였을 때 0.1 ~ 50 중량 % 이상, 바람직하게는 3 ~ 10 중량% 범위로 포함될 것이다.The antimicrobial composition of the present invention may be incorporated into the antimicrobial composition of the present invention in any amount as long as the active ingredient of the extract and the extract thereof exhibit antimicrobial activity. Usually, the composition is based on the total weight of the composition By weight, more preferably 0.1 to 50% by weight, and more preferably 3 to 10% by weight.
본 발명의 항미생물용 조성물은 유효성분인 감 미숙과 추출물의 항미생물 활성을 저해하지 않는 한, 그 유효성분인 이외에도 분산제와 담체 등을 포함하여 제조될 수 있다.The composition for an antimicrobial of the present invention may contain a dispersing agent, a carrier and the like in addition to the active ingredient thereof, so long as it does not inhibit the active ingredient, unrefined and the antimicrobial activity of the extract.
그러한 분산제로서 물, 알코올(예: 메틸 알코올, 에틸 알코올, 에틸렌 글리콜, 프로필렌 글리콜, 디에틸렌 글리콜, 글리세린 등), 케톤(예: 아세톤, 메틸 에틸 케톤 등), 에테르(예: 디옥산, 테트라하이드로푸란, 셀로솔브, 디에틸렌 글리콜 디메틸 에테르 등), 지방족 탄화수소(예: 헥산, 케로센 등), 방향족 탄화수소(예:벤젠, 톨루엔, 크실렌, 나프탈렌, 메틸 나프탈렌 등), 할로겐화 탄화수소(예: 클로로포름, 카본 테트라클로라이드 등), 산 아미드(예: 디메틸 포름아디드 등), 에스테르(예: 메틸 아세테이트 에스테르, 에틸 아세테이트 에스테르, 부틸 아세테이트 에스테르, 지방산 글리세린 에스테르 등), 니트롤(예: 아세토니트릴 등), 계면 활성제(고급 알코올 설페이트 에스테르, 알킬 설폰산, 알킬 알릴 설폰산, 4급 암모늄 염, 옥시 알킬 아민, 지방산 에스테르, 폴리알킬렌 옥시드 화합물, 안하이드로 소르비톨 화합물) 등을 들 수 있는데, 상기 분산제는 단독으로 또는 2종 이상의 혼합물로 본 발명의 항미생물 조성물에 포함되어 제조될 수 있다.Such dispersants include water, alcohols such as methyl alcohol, ethyl alcohol, ethylene glycol, propylene glycol, diethylene glycol, glycerin, etc., ketones such as acetone and methyl ethyl ketone, ethers such as dioxane, Aliphatic hydrocarbons such as hexane and kerosene; aromatic hydrocarbons such as benzene, toluene, xylene, naphthalene and methylnaphthalene; halogenated hydrocarbons such as chloroform, Carbon tetrachloride and the like), acid amides (e.g., dimethylformamide), esters (e.g., methyl acetate ester, ethyl acetate ester, butyl acetate ester, fatty acid glycerin ester and the like), nitrol (e.g., acetonitrile) Surfactants (higher alcohol sulfate esters, alkyl sulfonic acids, alkyl allyl sulfonic acids, quaternary ammonium salts, oxyalkylamines, fatty acid esters A polyalkylene oxide compound, and an anhydrous sorbitol compound). The dispersant may be prepared by incorporating the dispersant into the antimicrobial composition of the present invention, alone or in a mixture of two or more.
담체의 경우로서는 점토(예: 카올린, 벤토나이트, 산 점토 등), 활석(예: 활석 분말, 납석 분말 등), 실리카(예: 규조토, 규산 무수물, 운모 분말 등), 알루미나, 활성탄 등이 예시될 수 있으며, 이들 담체도 단독으로 또는 2종 이상의 혼합물로서 본 발명의 항미생물용 조성물에 포함되어 제조될 수 있다.Examples of the carrier include clay (for example, kaolin, bentonite, acid clay, etc.), talc (for example, talc powder and tin powder), silica (for example, diatomaceous earth, silicic anhydride, mica powder, etc.) These carriers may be prepared by being contained in the antimicrobial composition of the present invention alone or as a mixture of two or more kinds.
한편 본 발명의 항미생물용 조성물은 액체상, 고체상 및 기체상 중 임의의 상으로 제조될 수 있다. 또 본 발명의 항미생물용 조성물은 경구, 비경구 등 임의의 방식으로 투여될 수 있으며, 바람직하게는 국소 투여 방식으로 투여될 수 있다. 경구 투여 방식의 제형은 정제, 환제, 분제, 액제, 식품 형태 등을 들 수 있으며, 비경구 방식의 제형은 주사제, 국소 투여제(용액, 크림, 연고, 겔, 로션, 패치), 좌약, 살포제(식물에 적용하는 경우) 등을 들 수 있다. 특히 국소 투여 방식의 제형은 본 발명의 항미생물용 조성물을 천연 섬유나 합성 섬유로 된 담체에 함침시킨 것, 화장품이나 비누 등에 함유시킨 것 등을 포함한다.In addition, the antimicrobial composition of the present invention may be prepared in any of liquid, solid and gas phases. The antimicrobial composition of the present invention may be administered by any method such as oral, parenteral, or the like, and preferably, it may be administered by a local administration method. The parenteral formulation may be in the form of an injection, a topical preparation (solution, cream, ointment, gel, lotion, patch), a suppository, (When applied to plants) and the like. Particularly, topical administration formulations include those in which the antimicrobial composition of the present invention is impregnated with a carrier made of natural fibers or synthetic fibers, those contained in cosmetics, soaps, and the like.
본 발명의 항미생물용 조성물은 화장품, 식품, 약품 등의 제품으로 제조될 수 있으며, 이들 제품의 제조에 첨가되어 사용될 수 있다.
The antimicrobial composition of the present invention may be manufactured as a cosmetic product, a food, a medicine, or the like, and may be added to the production of these products.
전술한 바와 같이, 본 발명에 따르면 감 미숙과 추출물을 이용한 항염증용 조성물과 아토피성 피부염 개선용 조성물을 제공할 수 있다. As described above, according to the present invention, it is possible to provide a composition for antiinflammation and a composition for ameliorating atopic dermatitis using an extract and an extract.
본 발명의 조성물은 화장품, 약품, 식품 등으로 제품화되어 이용될 수 있다.
The composition of the present invention can be used as a cosmetic product, medicine, food or the like.
도 1은 감 미숙과 압착 추출액과 그 숙성물의 NO 생성 억제 활성을 보여주는 결과이다.
도 2 내지 4는 감 미숙과 압착 추출액과 그 숙성물의 염증성 사이토카인의 생성 억제 활성을 보여주는 결과이다.
도 5는 감 미숙과 압착 추출액과 그 숙성물의 PGE2 생성 억제 활성을 보여주는 결과이다.
도 6은 감 미숙과의 실온, 60℃, 100℃ 물 추출물과 감 미숙과 30%, 70% 에탄올 추출물의 TARC와 MDC 생성 억제 활성을 보여주는 결과이다.
도 7 및 도 8은 각각 감 미숙과 압착 추출액의 1년 및 3년 숙성물의 최소세균사멸농도를 보여주는 배양 사진이다.Fig. 1 shows the results of showing the NO production inhibitory activity of the unripe and squeezed extract and its aged material.
2 to 4 are the results showing the activity of inhibiting the production of inflammatory cytokines in the unripe and squeezed extracts and aged products thereof.
Fig. 5 shows the results of showing the inhibitory activity of PGE 2 on the unripe and squeezed extract and its aged material.
FIG. 6 shows the results of TARC and MDC inhibitory activities of water extracts at 60 ° C and 100 ° C at room temperature, and 30% and 70% ethanol extracts, respectively.
FIGS. 7 and 8 are photographs showing the minimum bacteriostatic concentration of 1-year and 3-year aged extracts of unripe and crushed extract, respectively.
이하 본 발명을 실시예 및 실험예를 참조하여 설명한다. 그러나 본 발명의 범위가 이러한 실시예 및 실험예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described with reference to Examples and Experimental Examples. However, the scope of the present invention is not limited to these examples and experimental examples.
<< 실시예Example > > 감 미숙과 추출물 또는 그 숙성물의 제조Preparation of extract and its aged product
<실시예 1> 감 미숙과 추출물의 제조 ≪ Example 1 >
제주에서 재배되는 감 미숙과를 6월경에 구입하여 본 실험의 재료로 사용하였다. 감 미숙과를 동결건조시킨 후 미세말로 갈아서 증류수를 이용하여 실온, 60℃, 100℃에서 2시간 이상 추출하고 또 에탄올을 이용하여 30%와 70% 에탄올로 2시간 이상 추출하였다. 얻어진 각 추출액은 감압 농축기를 이용하여 농축 후 동결건조기를 이용하여 수분을 완전히 제거한 후 아래의 실험에 사용하였다.Jeju, Jeju, was purchased in June and used as a material for this experiment. The extracts were then lyophilized and then extracted with distilled water at room temperature, 60 ℃ and 100 ℃ for more than 2 hours. The extracts were further extracted with ethanol at 30% and 70% ethanol for more than 2 hours. The obtained extracts were concentrated using a vacuum concentrator and completely free of water using a freeze dryer, and then used in the following experiments.
<실시예 2> 감 미숙과 압착 추출액과 그 숙성물 제조 <Example 2> Preparation immature persimmon extract and compression and its aging water
감 미숙과 세절물을 압착하여 추출하고 그 추출액을 여과하여 액상의 감 미숙과 압착 추출액을 제조하였다. 숙성물은 그 액상의 미숙과 추출물을 실온에서 각각 12월 및 36개월 동안 숙성하여(그대로 방치하여) 제조하였다.
The extracts were squeezed out and the extracts were filtered to produce liquid unsampled and compressed extracts. The aged material was prepared by immersing and immersing the liquid immature and extracts at room temperature for 12 months and 36 months, respectively.
<< 실험예Experimental Example > > 감 추출물 또는 그 Persimmon extract or its 숙성물의Aged 항염 활성, 아토피성 피부염 개선 활성 및 항균 활성 실험 Anti-inflammatory activity, atopic dermatitis improvement activity and antibacterial activity test
<< 실험예Experimental Example 1> 1> 항염 활성 실험Anti-inflammatory activity experiment
<실험예 1-1> NO ( Nitric oxide ) 생성 억제 평가 <Experimental Example 1-1> NO (Nitric oxide) Inhibitory evaluation
RAW 264.7 세포를 10% FBS가 첨가된 DMEM 배지를 이용하여 1.5×105 cells/㎖로 조절한 후 24 well plate 에 접종하고, 실시예의 시료와 LPS (1 ㎍/㎖)를 동시에 처리하여 24시간 배양하였다. 생성된 NO의 양은 Griess 시약 [1% (w/v) sulfanilamide, 0.1% (w/v) naphylethylenediamine in 2.5% (v/v) phosphoric acid]을 이용하여 세포배양액 중에 존재하는 NO2 -의 형태로 측정하였다. 세포배양 상등액 100 ㎕와 Griess 시약 100 ㎕를 혼합하여 96 well plates에서 10분 동안 반응시킨 후 540 nm에서 흡광도를 측정하였다. 생성된 NO의 양은 sodium nitrite (NaNO2)를 standard로 비교하였다.RAW 264.7 cells were adjusted to 1.5 × 10 5 cells / ml using DMEM medium supplemented with 10% FBS, and then inoculated on a 24-well plate. LPS (1 μg / ml) Lt; / RTI > The amount of produced NO Griess reagent [1% (w / v) sulfanilamide, 0.1% (w / v) naphylethylenediamine in 2.5% (v / v) phosphoric acid] by using the NO 2 present in the cell culture - in the form of Respectively. 100 μl of the cell culture supernatant and 100 μl of Griess reagent were mixed and reacted on 96-well plates for 10 minutes, and the absorbance was measured at 540 nm. The amount of NO produced was compared with sodium nitrite (NaNO 2 ) as standard.
본 실험에서는 상기 <실시예 2>의 압착 추출액과 그것의 숙성물을 시료로 사용하였으며, 결과를 [도 1]에 나타내었다.In this experiment, the compressed extract of Example 2 and its aged material were used as a sample, and the results are shown in FIG.
[도 1]를 참조하여 보면, 압착 추출액과 비하여 숙성물 시료가 NO 생성 억제 활성이 높음을 알 수 있으며, 1년 숙성물보다 3년 숙성물의 활성이 더 높음을 알 수 있다. 1, it can be seen that the aged samples have higher activity of inhibiting the NO production than the squeezed extract, and that the activity of 3-year-aged water is higher than that of 1-year aged water.
<실험예 1-2> 염증성 사이토카인( TNF -α, IL -1β 및 IL -6)의 생성 억제 활성 평가 <Experimental Example 1-2> Evaluation of inhibitory activity on the production of inflammatory cytokines ( TNF- α, IL- 1β and IL- 6)
RAW 264.7 세포 (1.5×105 cells/㎖)를 DMEM 배지를 이용하여 24 well plate 에 접종하고, 5% CO2 항온기에서 18 시간 전 배양하였다. 이후 배지를 제거하고 실시예의 시료와 LPS (1 ㎍/㎖)를 동시에 처리하여 전 배양과 동일 조건에서 배양하였다. 24 시간 후 배양 배지를 원심분리 (12,000 rpm, 3 분)하여 얻어진 상층액의 염증성 사이토카인의 생성 함량을 측정하였다. 염증성 사이토카인은 mouse enzyme-linked immnunosorbent assay (ELISA) kit (R&D Systems Inc., Minneapolis, MN, USA)를 이용하여 정량하였으며 standard 에 대한 표준곡선의 r2 값은 0.99 이상이었다.RAW 264.7 cells (1.5 × 10 5 cells / ml) were inoculated into a 24-well plate using DMEM medium, and cultured in 5% CO 2 And cultured in a thermostat for 18 hours. After the medium was removed, the sample of Example and LPS (1 / / ml) were simultaneously treated and cultured under the same conditions as the pre-culture. After 24 hours, the production of inflammatory cytokines in the supernatant obtained by centrifuging the culture medium (12,000 rpm, 3 minutes) was measured. Inflammatory cytokines were quantified using the mouse enzyme-linked immnunosorbent assay (ELISA ) kit (R & D Systems Inc., Minneapolis, MN, USA) r 2 value of the standard curve for the standard was at least 0.99.
본 실험에서도 상기 <실시예 2>의 압착 추출액과 그것의 숙성물을 시료로 사용하였으며, <실시예 2>의 압착 추출액과 그것의 숙성물의 TNF-α, IL-1β 및 IL-6의 생성 억제 활성을 각각 [도 2] 내지 [도 4]에 나타내었다. In this experiment, the crushed extract of Example 2 and its aged material were used as samples, and the production of TNF-α, IL-1β and IL-6 in the pressurized extract of Example 2 and its aged material was inhibited The activities are shown in FIG. 2 to FIG. 4, respectively.
[도 2] 내지 [도 4]를 참조하여 보면, 상기 [도 1]의 NO 생성 억제 활성과 유사한 경향을 보이면서, 압착 추출액, 그것의 1년 숙성물 및 그것의 3년 숙성물 순으로 TNF-α, IL-1β 및 IL-6의 생성 억제 활성이 높음을 알 수 있다.2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, α, IL-1β and IL-6, respectively.
<실험예 1-3> PGE 2 생성 억제 활성 평가 <Experimental Example 1-3> Evaluation of inhibitory activity of PGE 2 formation
RAW 264.7 세포를 DMEM 배지를 이용하여 1.5×105 cells/㎖로 조절한 후 24 well plate 에 접종하고, 5% CO2 항온기에서 18시간 전 배양 하였다. 이후 배지를 제거하고 실시예의 시료와 LPS (1 ㎍/㎖)를 동시에 처리하여 전배양과 동일 조건에서 배양하였다. 24시간 후 PGE2를 측정하기 위해 배양 배지를 원심분리 (12,000 rpm, 3 min)하여 상층액을 얻었다. PGE2의 측정은 PGE2 ELISA kit (R&D Systems Inc., Minneapolis, MN, USA)를 이용하여 정량하였으며 standard 에 대한 표준곡선의 r2 값은 0.99 이상이었다.RAW 264.7 cells were adjusted to 1.5 × 10 5 cells / ml using DMEM medium, and then inoculated into a 24-well plate and cultured for 18 hours in a 5% CO 2 incubator. After the medium was removed, the sample of the example and LPS (1 / / ml) were simultaneously treated and cultured under the same conditions as the pre-culture. After 24 hours, the supernatant was obtained by centrifuging the culture medium (12,000 rpm, 3 min) to measure PGE 2 . PGE 2 was quantitated using a PGE 2 ELISA kit (R & D Systems Inc., Minneapolis, MN, USA). The r 2 value of the standard curve for the standard was 0.99 or more.
본 실험에서도 상기 <실시예 2>의 압착 추출액과 그것의 숙성물을 시료로 사용하였으며, 결과를 [도 5]에 나타내었는데, 마찬가지로 압착 추출액, 그것의 1년 숙성물 및 그것의 3년 숙성물 순으로 활성이 높게 나타났다.In this experiment, the compressed extract of Example 2 and its aged material were used as a sample. The results are shown in Fig. 5, and similarly, the press extract, its 1-year aged material and its 3-year aged material Respectively.
<실험예 1-4> 세포독성 평가 ( LDH assay ) <Experimental Example 1-4> Evaluation of cytotoxicity ( LDH assay )
RAW 264.7 세포 (1.5×105 cells/㎖)를 DMEM 배지에 실시예의 시료와 LPS (1 ㎍/㎖)를 동시 처리하여 24시간 배양 한 후 배양 배지를 얻어 3,000 rpm에서 5분간 원심분리 하였다. LDH (lactate dehydrogenase) assay는 non-radioactive cytotoxicity assay kit (Promega)를 이용하여 측정했으며, 96 well plate에 원심 분리하여 얻은 배양 배지 50 ㎕와 reconstituted substrate mix를 50 ㎕를 넣고, 실온에서 30분 반응시킨 후 50 ㎕의 stop solution을 넣은 후 microplate reader (Bio-TEK Instruments Inc., Vermont, WI, USA)를 사용하여 490 nm에서 흡광도를 측정하였다. 각 시료군에 대한 평균 흡광도 값을 구하였으며, 대조군 (LDH control, 1:5000)의 흡광도 값과 비교하여 세포독성을 평가하였다.RAW 264.7 cells (1.5 × 10 5 cells / ml) were co-treated with DMEM medium and LPS (1 μg / ml) in DMEM medium for 24 hours, and then cultured for 3 minutes at 3,000 rpm for 5 minutes. The LDH (lactate dehydrogenase) assay was performed using a non-radioactive cytotoxicity assay kit (Promega). 50 μl of the culture medium obtained by centrifugation on a 96-well plate and 50 μl of the reconstituted substrate mix were added and reacted at room temperature for 30 minutes After adding 50 μl of stop solution, absorbance was measured at 490 nm using a microplate reader (Bio-TEK Instruments Inc., Vermont, WI, USA). The average absorbance values for each sample group were determined and compared with the absorbance values of the control (LDH control, 1: 5000) to evaluate cytotoxicity.
본 실험에서도 상기 <실시예 2>의 압착 추출액과 그것의 숙성물을 시료로 사용하였으며, 결과를 [도 1]에 함께 나타내었는데, [도 1]를 참조하여 보면 실시예의 시료는 특별한 세포독성을 보이지 않음을 보여주며, 이는 앞서 염증 관련 인자의 생성 억제 활성이 세포독성에 의한 결과가 아님을 알 수 있다.In the present experiment, the compressed extract of Example 2 and its aged material were used as a sample. The results are also shown in FIG. 1. Referring to FIG. 1, the samples of the Examples show specific cytotoxicity , Indicating that the inhibitory activity on the production of inflammatory factors is not a result of cytotoxicity.
<< 실험예Experimental Example 2> 2> 아토피성 피부염 개선 활성 실험Experiment to improve atopic dermatitis
<실험예 2-1> 아토피성 피부염 유발 인자인 TARC 와 MDC 생성 억제 활성 평가 <Experimental Example 2-1> Evaluation of inhibitory activity of TARC and MDC which are atopic dermatitis inducers
HaCaT 세포(3.0×105cells/mL)를 DMEM 배지를 이용하여 세포수를 조절한 후 24 well plate 에 접종하고, 5% CO2 항온기에서 18시간 전 배양 하였다. 이후 배지를 제거하고 HaCaT 세포는 실시예의 추출물 시료 50 ㎕와 450 ㎕의 TNF-α+IFN-γ(10 ng/mL)를 함유한 새로운 배지를 동시에 처리하였고 전배양과 동일 조건에서 배양하였다. 24 시간 후 배양 배지를 원심분리 (12,000 rpm, 3 분)하여 얻어진 상층액의 아토피 유발 인자 생성 함량을 측정하였다. TARC와 MDC의 정량은 mouse enzyme-linked immnunosorbent assay (ELISA) kit (R&D Systems Inc., Minneapolis, MN, USA)를 이용하여 정량하였으며 standard에 대한 표준곡선의 r2값은 0.99 이상이었다.HaCaT cells (3.0 × 10 5 cells / mL) were inoculated into a 24-well plate and DMEM culture medium. Cells were cultured in a 5% CO 2 incubator for 18 hours. Subsequently, the medium was removed and HaCaT cells were treated with 50 μl of the extract sample of Example and 450 μl of TNF-α + IFN-γ (10 ng / ml) in a fresh medium and cultured under the same conditions as the pre-culture. After 24 hours, the culture medium was centrifuged (12,000 rpm, 3 minutes), and the amount of atopy inducing factor produced in the supernatant was measured. Determination of TARC and MDC was quantified using the mouse enzyme-linked immnunosorbent assay (ELISA ) kit (R & D Systems Inc., Minneapolis, MN, USA) r 2 value of the standard curve for the standard was at least 0.99.
본 실험에서는 <실시예 1>의 각 조건별 추출물만을 시료로 사용하였다.In this experiment, only the extract of each condition of Example 1 was used as a sample.
결과를 [도 6]에 나타내었다. [도 6]을 참조하여 보면 감 미숙과 100℃ 추출물 및 30% 에탄올 추출물의 활성이 특별히 높음을 보여준다.The results are shown in Fig. Referring to FIG. 6, the activity of Safflower extract, 100 ° C extract and 30% ethanol extract are particularly high.
한편 상기 <실시예 1>의 각 조건별 추출물 시료의 세포독성에 대한 실험을 상기 <실험예 1-4>와 동일한 방법으로 수행하고 그 결과를 [도 6]에 함께 나타내었는데, 특별한 세포독성을 보이지 않았다. 이는 아토피성 피부염 유발 인자인 TARC와 MDC 생성 억제 활성이 세포독성에 의한 결과가 아님을 말해준다고 할 수 있다.Meanwhile, the experiment on the cytotoxicity of the extract sample according to each condition of Example 1 was performed in the same manner as in <Experimental Example 1-4>, and the results thereof are shown in FIG. 6 together. I did not see it. This suggests that the inhibitory activity of TARC and MDC, which are atopic dermatitis inducing factors, is not a result of cytotoxicity.
<실험예 2-2> 아토피성 피부염 개선 활성에 대한 임상시험 <Experimental Example 2-2> Clinical trial for improving atopic dermatitis
아토피성 피부염 개선에 대한 임상실험을 위하여 아래의 [표 1]의 성분 및 함량으로 영양 로션을 제조하였다.Nutritional lotions were prepared with the ingredients and contents shown in the following Table 1 for the clinical test for the improvement of atopic dermatitis.
(중량%)content
(weight%)
아토피성 피부염 개선 활성은 5세 이상 아토피성 피부염 증상을 갖고 있는 남녀 60명을 대상으로 3 그룹으로 나눈 다음, 각 그룹에 상기 실시예의 추출물이 함유된 각 영양로션을 하루 2~3회 8주간 도포하게 하였다.The atopic dermatitis improving activity was divided into three groups of 60 men and women having symptoms of atopic dermatitis over 5 years old and each nutrient lotion containing the extract of the above example was applied for 2 to 3 times a day for 8 weeks .
시험 시작 전 및 8주가 지난 후에 SCORAD 지수(The European Task Force on Atopic Dermatitis가 개발한 아토피 중증도 평가 지수로 아토피 증상이 심할수록 높은 수치로 나타남)을 측정하였다.Before and after the start of the study, the SCORAD Index was developed by the European Task Force on Atopic Dermatitis, and the severity of atopic symptoms was high.
결과를 평균 ± 표준편차로로 아래의 [표 2]에 나타내었다.The results are shown in Table 2 below as mean ± standard deviation.
상기 [표 2]의 결과는 <실시예 1>의 상온 추출물 함유 영양로션의 경우 유의차를 보이지 않았지만, <실시예 1>의 100℃ 추출물 및 30% 에탄올 추출물의 경우는 유의차를 보였음을 보여주며 또한 SCORAD 지수의 평균값도 뚜렷하게 낮아졌음을 보여준다. The results of the above Table 2 showed no significant difference in the case of the nutrient lotion containing the normal temperature extract of Example 1, but the 100 ° C extract and the 30% ethanol extract of Example 1 showed a significant difference And the mean value of the SCORAD index is also significantly lowered.
통계 처리Statistical processing
상기 임상실험의 결과 정리 및 분석을 위하여 Excel program과 통계 소프트웨어인 SPSS Window. version 10.1을 사용하였으며, 통계의 유의성을 위하여 유의 수준 0.05를 설정하였고, 분석을 위하여 이용되는 통계적 방법은 독립표본 T-검정, 대응 표본 T-검정 해석방법으로 분석하였다.For the analysis and analysis of the results of the clinical trial, Excel program and statistical software SPSS Window. Version 10.1 was used. For statistical significance, a significance level of 0.05 was set. Statistical methods used for analysis were analyzed by the independent sample T-test and the corresponding sample T-test.
<< 실시예Example 3> 3> 항균 활성 실험Experiment of antibacterial activity - - 최소세균사멸농도(Minimum bactericidal concentration ( MinimalMinimal bactericidalbactericidal concentration, concentration, MBCMBC )의 측정)
본 실험에 사용한 균주는 피부에서 흔히 검출되는 균주인 스타필로코쿠스 아우레우스(S. aureus KCTC 1927)를 사용하였고, 배지는 Trypticase soy agar/broth(TSA)(Difco 사, USA)를 사용하였으며, 37℃에서 배양하였다. Staphylococcus aureus ( S. aureus KCTC 1927), a strain commonly found in the skin, was used and the medium used was Trypticase soy agar / broth (TSA) (Difco, USA) , And cultured at 37 ° C.
최소세균사멸농도의 측정은 농도별로 실시예의 시료가 함유된 고체배지에 해당 균주의 배양액 100㎕씩 직접 도말하였고 그 균주를 배양한 후 plate 상에서 육안으로 관찰되는 colony 수를 직접 계수하였다. 이때 확인되어지는 colony 수가 배양액으로부터 접종한 초기 접종균수의 99.9%를 사멸시키는 효과를 나타내는 것으로 확인 되어진 경우 이때의 처리농도를 최소세균사멸농도(MBC)로 정하였다(Cohen MA, Huband MD, Yoder SL, Gage JW, Roland GE., 1998, Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies. J Antimicrob Chemother . 41(6): 605-14).Measurement of the minimum bacterial killing concentration was carried out by directly spraying 100 μl of the culture solution of the strain in the solid medium containing the sample of the concentration by concentration and directly counting the number of colonies observed visually on the plate after the strain was cultured. When the colony count was confirmed to have the effect of killing 99.9% of the inoculated bacteria inoculated from the culture broth, the treatment concentration was determined as the minimum bacterial killing concentration (MBC) (Cohen MA, Huband MD, Yoder SL , Gage JW, Roland GE, 1998, Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies J Antimicrob Chemother . 41 (6): 605-14).
본 실험에서도 상기 <실시예 2>의 압착 추출액과 그것의 숙성물을 시료로 사용하였으며, 결과를 아래의 [표 3]에 나타내었다.In this experiment, the squeezed extract of Example 2 and the aged material thereof were used as samples, and the results are shown in Table 3 below.
상기 [표 3]의 결과는 압착 추출액 시료의 경우는 스타필로코쿠스 아우레우스에 대해 MBC가 측정되지 않았으나 숙성물 시료의 경우는 모두 2 mg/mL의 최소사멸농도를 나타내었음을 보여준다. The results of the above Table 3 show that MBC was not measured for Staphylococcus aureus in the case of the squeezed extract, but all of the aged samples showed a minimum killing level of 2 mg / mL.
[도 7] 및 [도 8]에 각각 1년 숙성물 및 3년 숙성물의 농도별 미생물 배양 사진을 나타내었다.
[Fig. 7] and [Fig. 8] are photographs showing microbial cultures of 1-year aged water and 3-year aged water, respectively.
Claims (8)
A composition for antiinflammation comprising an aged product of an unbaked and pressed extract as an active ingredient.
상기 감 미숙과 압착 추출액의 숙성물은 감 미숙과 압착 추출액을 상온에서 3년 이상 방치하여 얻어진 것을 특징으로 하는 항염증용 조성물.
The method according to claim 1,
The composition for antiinflammation according to claim 1, wherein the aged product of the unsampled and compressed extract is obtained by allowing the unrefined and compressed extract solution to stand at room temperature for 3 years or more.
상기 감 미숙과 압착 추출액의 숙성물은 감 미숙과 압착 추출액을 상온에서 1년 이상 방치하여 얻어진 것을 특징으로 하는 항염증용 조성물.
The method according to claim 1,
The composition for antiinflammation according to claim 1, wherein the aged product of the unsampled and compressed extract is obtained by allowing the unrefined and compressed extract solution to stand at room temperature for 1 year or more.
상기 조성물은 화장품 조성물인 것을 특징으로 하는 조성물.
4. The method according to any one of claims 1 to 3,
Wherein the composition is a cosmetic composition.
상기 조성물은 약제학적 조성물인 것을 특징으로 하는 조성물.
4. The method according to any one of claims 1 to 3,
Wherein the composition is a pharmaceutical composition.
상기 조성물은 식품 조성물인 것을 특징으로 하는 조성물.
4. The method according to any one of claims 1 to 3,
Wherein the composition is a food composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120122087A KR101455842B1 (en) | 2012-10-31 | 2012-10-31 | Anti-Inflammation Composition and an Improvment Composition of Atopic Dermatitis Using an Extract of Immature Fruit of Diospyros kaki |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120122087A KR101455842B1 (en) | 2012-10-31 | 2012-10-31 | Anti-Inflammation Composition and an Improvment Composition of Atopic Dermatitis Using an Extract of Immature Fruit of Diospyros kaki |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR20140021196A Division KR101490512B1 (en) | 2014-02-24 | 2014-02-24 | Anti-Inflammation Composition and an Improvment Composition of Atopic Dermatitis Using an Extract of Immature Fruit of Diospyros kaki |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20140055375A KR20140055375A (en) | 2014-05-09 |
KR101455842B1 true KR101455842B1 (en) | 2014-11-03 |
Family
ID=50887038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120122087A KR101455842B1 (en) | 2012-10-31 | 2012-10-31 | Anti-Inflammation Composition and an Improvment Composition of Atopic Dermatitis Using an Extract of Immature Fruit of Diospyros kaki |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101455842B1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104548036A (en) * | 2015-01-15 | 2015-04-29 | 葛海 | Traditional Chinese medicine for treating chronic hypertrophic rhinitis |
CN104666833A (en) * | 2015-03-30 | 2015-06-03 | 李燕 | Chinese medicinal composition for treating uterine fibroids and preparation method thereof |
CN107823243A (en) * | 2017-11-30 | 2018-03-23 | 广西南宁栩兮科技有限公司 | The extracting method of flavones in a kind of persimmon seed |
KR102590469B1 (en) * | 2020-09-25 | 2023-10-17 | 이명진 | Immature fruit of diospyros kaki liquid extractor and method for extracting liquid of immature Fruit of diospyros kaki with anti-allergic and anti-inflammatory effects using the liquid extractor, and extract extracted therefrom |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090084159A (en) * | 2008-01-31 | 2009-08-05 | 경북대학교 산학협력단 | Composition for treating immune related disease comprising extract of diospyros kaki thunb. or tannin as an active ingredient |
KR20120031695A (en) * | 2010-09-27 | 2012-04-04 | 재단법인 한국한방산업진흥원 | A composition comprising the extract of diospyros kaki thunb as an active ingredient for preventing and treating inflammatory disease |
-
2012
- 2012-10-31 KR KR1020120122087A patent/KR101455842B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090084159A (en) * | 2008-01-31 | 2009-08-05 | 경북대학교 산학협력단 | Composition for treating immune related disease comprising extract of diospyros kaki thunb. or tannin as an active ingredient |
KR20120031695A (en) * | 2010-09-27 | 2012-04-04 | 재단법인 한국한방산업진흥원 | A composition comprising the extract of diospyros kaki thunb as an active ingredient for preventing and treating inflammatory disease |
Non-Patent Citations (2)
Title |
---|
우상욱. 경북대학교 일반대학원 석사학위논문. "T-bet promoter assay와 아토피 유발 동물 모델을 이용한 감 추출물의 염증질환 억제 효과" (2008년) * |
허진철 등. 한국식품저장유통학회지. 제15권, 제5호, 749-753 페이지 (2008년 10월) * |
Also Published As
Publication number | Publication date |
---|---|
KR20140055375A (en) | 2014-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101448207B1 (en) | Anti-inflammatory Composition Using a Flower Extract of Citrus unshiu | |
KR101618330B1 (en) | Pharmaceutical Composition comprising Lactococcus chungangensis for Previnting or Treating Inflammatory disease | |
KR101455842B1 (en) | Anti-Inflammation Composition and an Improvment Composition of Atopic Dermatitis Using an Extract of Immature Fruit of Diospyros kaki | |
KR101616011B1 (en) | Composition for Anti-imflammation Using an Extract of Immature Fruits of Litsea japonica or Compounds Isolated Therefrom | |
EP1312373A1 (en) | Antiallergic agents, drugs, foods, drinks or cosmetics containing them and process for producing the same | |
KR101368293B1 (en) | Anit-inflammation Composition and Skin-whitening Compostion Using a Fermentation Product of Kiwifruits | |
KR101516317B1 (en) | Anti-inflammatory Composition Using an Extract of Undariopsis peterseniana | |
KR102337965B1 (en) | Composition for Anti-inflammation Using an Extract of Lemon Peel and a Root Extract of Sophora flavescens | |
KR101367961B1 (en) | Compositoin for Improving Atopic Dermatitis | |
KR101490512B1 (en) | Anti-Inflammation Composition and an Improvment Composition of Atopic Dermatitis Using an Extract of Immature Fruit of Diospyros kaki | |
KR20120077357A (en) | Anti-inflammatory composition and anti-oxidative composition using an extract of teucrium veronicoides | |
KR20120036924A (en) | Essential oil extract of neolistea sericea having anti-inflammatory activity and anti-microbial activity and use thereof | |
KR20160080513A (en) | Anti-inflammation Composition Using Extracts of Zizania latifolia | |
KR101900480B1 (en) | Antioxidant Composition Using an Extract of Polygonum amphibium | |
KR101925724B1 (en) | Anti-inflammation Composition Using an Extract of Scirpus tabernaemontani | |
KR20110036318A (en) | Essential oil extract of neolistea sericea having anti-inflammatory activity and anti-microbial activity and use thereof | |
KR20160111126A (en) | Composition for Improving Atopic Dermatitis Using Fermented Products of Fruit of Diospyros kaki | |
KR20130009238A (en) | Composition for improving skin diseases | |
KR101722472B1 (en) | Anti-inflammation Composition Using Litsea japonica Extract and Litseakolide D2 Isolated from the Same | |
KR101396572B1 (en) | Anti-inflammatory Composition Using a Flower Extract of Hallabong tangor | |
KR101491705B1 (en) | Anti-inflammation Composition Using Acrosorium yendoi Extracts | |
KR102254895B1 (en) | Composition for Anti-inflammation Using Carex glabrescens | |
KR101242941B1 (en) | Composition for Atopy Skin Using an Extract of Bamboo Leaves and an Extract of Root of Polygonum | |
KR20150032511A (en) | Antioxidant Composition Anti-inflammatory Composition Using an Extract of Cocculus trilobus | |
KR20220053474A (en) | Composition for Anti-inflammation Using Acuminatin Isolated from an Extract of Magnolia liliflora |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20181022 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20191106 Year of fee payment: 6 |